TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) Investor Investigation Over Potential Violations Of Securities Laws Announced

  • If you purchased shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

July 28, 2016 (Update) - On July 26, 2016, Tokai Pharmaceuticals Inc announced that it was ending a late-stage trial of galeterone, its potential prostate cancer therapy. Tokai Pharmaceuticals Inc stated that it did not believe the phase 3 study would meet its primary endpoint.Shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI) declined from $18.39 per share in September 2014 to as low ...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: